3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
3
NET
1
Lymphoid
1
Conditions
Lymphoma, Follicular
3
Lymphoma
3
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Hodgkin Disease
2
Uveal Melanoma
1
Sezary Syndrome
1
Recurrence
1
Primary Myelofibrosis
1
Mycosis Fungoides
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell
1
Central Nervous System Neoplasms
1
Carcinoma, Neuroendocrine
1
Cancer That is Associated With a Chronic Viral Infection
1
Interventions
pembrolizumab
1
avelumab
1
Fluorodeoxyglucose F18
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Neuroendocrine
×
avelumab
×
Lymphoid
×
Clear all
NCT03147404
2019-12-30
MS100070-0177
Samsung Medical Center
Phase 2
Completed
14 enrolled